The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

March 08, 2007 06:30 ET

Medipattern Launches B-CAD™ 1.2 at Northwestern

Lynn Sage Breast Center In Chicago Uses B-CAD To Track At-Risk Patients

TORONTO, ONTARIO--(CCNMatthews - March 8, 2007) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided diagnosis (CAD) solutions for medical imaging, whose mission is to reduce the number of unnecessary biopsies performed to diagnose cancer, is pleased to announce the installation of its latest version of B-CAD, 1.2, at the Lynn Sage Breast Center of Northwestern University Memorial Hospital, Chicago, IL. B-CAD 1.2 for breast ultrasound imaging associates multiple views of the same breast lesion and can track multiple lesions for the same patient in one record. It performs CAD and electronically analyzes breast masses using the American College of Radiology (ACR) BI-RADS® (Breast Imaging Reporting and Data System) feature categories and their descriptors to help increase accuracy and consistency. Version 1.2 documents all of the information required to track multiple lesions and completes the procedure by automatically documenting the results. Version 1.2 is production-released and available for immediate shipment.

More generally, B-CAD segments a lesion and automatically reviews key features to characterize it. B-CAD then uses radiologists' input along with the BI-RADS® feature category and descriptor checklists to generate a BI-RADS® score for the lesion, providing consistency in results and making it possible to follow a benign lesion from visit to visit. Finally, B-CAD records all of the findings automatically and generates a structured report in natural language.

"Most breast masses are not cancer. Of course, any mass that has characteristics of cancer will be biopsied immediately. But when a mass that we think is benign grows or changes, then we need to be concerned about a possible malignancy. We need to be able to image these masses in a standardized, reproducible way to determine a significant change." said Dr. Ellen Mendelson, Chief of Breast and Women's Imaging at the Lynn Sage Breast Center. "The ACR published the BI-RADS® lexicon to characterize breast lesions using ultrasound imaging by combining multiple features such as shape, margin, and orientation within the breast. Systematically tracking lesions seen via ultrasound is important.

"Medipattern's B-CAD gives breast imaging physicians the ability to assess lesions easily by automatically applying the BI-RADS® analysis methods. B-CAD can capture all of the image detail and can report it more quickly than using conventional methods.

"B-CAD utilizes BI-RADS® feature categories and makes lesion analysis possible while the patient is still being scanned - real time. This will increase efficiency and may help in differentiating between benign and malignant masses, with the goal of reducing the number of unnecessary biopsies in the future."

The Lynn Sage Breast Center is one of the top breast care facilities in the United States. The center has noted a definite increase in all patient procedures over the past year. This is believed to be due to the steady increase in the volume of screening examinations being performed as women comply with recommendations.

"Tracking multiple lesions in the same case record in B-CAD 1.2 marks a significant step forward in CAD. Organizing and associating multiple views and analyzing feature category characteristics from multiple views for a given lesion improves consistency and saves time. Version 1.2 also tracks multiple lesions with full detail as part of the same record. Using B-CAD as part of the procedure with breast ultrasound can identify breast lesions so that physicians can act quickly and appropriately for the millions of women already in periodic follow up," said Jeff Collins, CEO of Medipattern.

Upcoming Events:

Medipattern will participate in the following events:

- European Congress of Radiology, March 9 to 13, 2007,in Vienna, Austria at Booth 45 Expo Hall A, as well as the Kodak, Confirma, Sectra, and Cedara booths.

- AIUM 2007, March 15 to 18, 2007 in New York City at Booth 217.

- Society of Breast Imaging, April 14 to 17 2007 in Hollywood Florida.

- China MED 2007, April 22 to 24, Beijing, PRC.

- American Society of Breast Surgeons Annual Meeting, May 2 to 7, 2007 Phoenix, AZ.

- Breast Imaging Course sponsored by Stanford, May 2 to 6 in Las Vegas, NV.

- Chicago International Breast Imaging Symposium October 3 to 7, 2007, Chicago, IL.

- RSNA, November 25 to 29, 2007, Chicago, IL.

About The Medipattern Corporation

Medipattern develops computer-aided diagnosis (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CAD MRI™. Both have received awards for innovation in the industry. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. Medipattern was founded to design software products that save lives, detect breast cancer, and reduce the number of unnecessary biopsies in women referred for diagnosis of potential breast cancer. Please visit the company's website at: www.medipattern.com.

About B-CAD™

B-CAD, a computer-assisted diagnosis software system, segments a selected breast lesion and automatically reviews key features to characterize it. B-CAD then uses radiologists' input along with the American College of Radiology'a BI-RADS® (Breast Imaging Report and Data System) feature category and descriptor checklists to generate a BI-RADS® score for each lesion, providing consistency in results and making it possible to follow a lesion from visit to visit. Finally, B-CAD records all of the findings automatically and generates a structured report in natural language.

B-CAD™ and B-CAD MRI™ are trademarks of The Medipattern Corporation.

Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information